Clinical analysis of 64 cases of multidrug resistant pulmonary tuberculosis
10.3760/cma.j.issn.1008-6706.2018.17.016
- VernacularTitle: 耐多药肺结核64例临床分析
- Author:
Qijie ZHAO
1
;
Yunyun ZHANG
2
;
Weizhen YE
1
Author Information
1. Department of Infection, the First Hospital of Ninghai, Ninghai, Zhejiang 315600, China
2. Department of Obstetrics and Gynecology, the First Hospital of Ninghai, Ninghai, Zhejiang 315600, China
- Publication Type:Journal Article
- Keywords:
Tuberculosis, multidrug resistant;
Tuberculosis;
Treatment outcome
- From:
Chinese Journal of Primary Medicine and Pharmacy
2018;25(17):2240-2243
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To explore the effect of previous treatment on the efficacy of multidrug resistant pulmonary tuberculosis (MDR-TB) patients.
Methods:From February 2015 to February 2017, 64 cases with MDR-TB who received treatment in the First Hospital of Ninghai were collected.All patients received antituberculous therapy for 6 months.The clinical data were retrospectively analyzed.The factors that influence the efficacy of MDR-TB patients were evaluated by multivariate logistic regression analysis.
Results:After standard chemotherapy for MDR-TB patients, the incidence of chest radiographic lesions in primary and relapsed MDR-TB patients was 18 cases(81.82%) and 21 cases(50.00%), respectively.There was statistically significant difference between the two groups (χ2=22.835, P<0.05). The cavity closure rate of MDR-TB patients after primary treatment and relapse was 54.55% and 40.48%, respectively, and there was significant difference between the two groups (χ2=8.693, P<0.05). After standard chemotherapy for MDR-TB patients, the cure rates of primary and recurrent MDR-TB patients were 18 cases(81.82%) and 23 cases (54.76% ), respectively, there was statistically significant difference between the two groups (χ2=21.791, P<0.05).
Conclusion:The effect of initial treatment of MDR-TB is better than recurrent MDR-TB, so it is necessary to strengthen the surveillance of drug resistance in patients with tuberculosis and to find the disease as soon as possible.Early treatment of MDR-TB is the best option for patients.
